Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Carmot Therapeutics


All Data

Filters Filter refresh
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CT-868

            Therapeutic Area: Endocrinology Product Name: CT-868

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: $47.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing September 30, 2020


            The funding will support initiation early in 2021 of a 26-week dose ranging phase 2 study for CT-868 and phase 1-2 studies for CT-388 and involve more than 300 patients.